References
- Annapoorani, A., Umamageswaran, V., Parameswari, R., Pandian, S. K., & Ravi, A. V. (2012). Computational discovery of putative quorum sensing inhibitors against LasR and RhlR receptor proteins of Pseudomonas aeruginosa. Journal of Computer-Aided Molecular Design, 26(9), 1067–1077. https://doi.org/https://doi.org/10.1007/s10822-012-9599-1
- Association Diabetes Association. (2010). Diagnosis and classification of diabetes mellitus. Diabetes Care, 33(Suppl 1), S62–S69. https://doi.org/https://doi.org/10.2337/dc10-S062
- Association Diabetes Association. (2018). 10. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2018. Diabetes Care, 41(Suppl 1), S105. https://doi.org/https://doi.org/10.2337/dc18-S010
- Baell, J. B., & Holloway, G. A. (2010). New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of Medicinal Chemistry, 53(7), 2719–2740. https://doi.org/https://doi.org/10.1021/jm901137j
- Bender, A., & Glen, R. C. (2005). A discussion of measures of enrichment in virtual screening: Comparing the information content of descriptors with increasing levels of sophistication. Journal of Chemical Information and Modeling, 45(5), 1369–1375. https://doi.org/https://doi.org/10.1021/ci0500177
- Bologa, C. G., Olah, M. M., & Oprea, T. I. (2006). Chemical database preparation for compound acquisition or virtual screening (Bioinformatics and Drug Discovery (pp. 375–388). Springer. https://doi.org/https://doi.org/10.1385/1-59259-964-8:375
- Brownlee, M. (2005). The pathobiology of diabetic complications: A unifying mechanism. Diabetes, 54(6), 1615–1625. https://doi.org/https://doi.org/10.2337/diabetes.54.6.1615
- Chen, Y., Zheng, Y., Fong, P., Mao, S., & Wang, Q. (2020). The application of the MM/GBSA method in the binding pose prediction of FGFR inhibitors. Physical Chemistry Chemical Physics, 22(17), 9656–9663. https://doi.org/https://doi.org/10.1039/d0cp00831a
- Choudhary, S., & Silakari, O. (2019). hCES1 and hCES2 mediated activation of epalrestat-antioxidant mutual prodrugs: Unwinding the hydrolytic mechanism using in silico approaches. Journal of Molecular Graphics & Modelling, 91, 148–163. https://doi.org/https://doi.org/10.1016/j.jmgm.2019.06.012
- Cosconati, S., Marinelli, L., La Motta, C., Sartini, S., Da Settimo, F., Olson, A. J., & Novellino, E. (2009). Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening. Journal of Medicinal Chemistry, 52(18), 5578–5581. https://doi.org/https://doi.org/10.1021/jm901045w
- Costantino, L., Rastelli, G., Gamberini, M. C., & Barlocco, D. (2000). Pharmacological approaches to the treatment of diabetic complications. Expert Opinion on Therapeutic Patents, 10(8), 1245–1262. https://doi.org/https://doi.org/10.1517/13543776.10.8.1245
- de la Fuente, J. Á., & Manzanaro, S. (2003). Aldose reductase inhibitors from natural sources. Natural Product Reports, 20(2), 243–251. https://doi.org/https://doi.org/10.1039/b204709h
- de la Fuente, J. Á., Manzanaro, S., Martín, M. J., de Quesada, T. G., Reymundo, I., Luengo, S. M., & Gago, F. (2003). Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product. Journal of Medicinal Chemistry, 46(24), 5208–5221. https://doi.org/https://doi.org/10.1021/jm030957n
- Dong, J., Wang, N.-N., Yao, Z.-J., Zhang, L., Cheng, Y., Ouyang, D., Lu, A.-P., & Cao, D.-S. (2018). ADMETlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. Journal of Cheminformatics, 10(1), 29. https://doi.org/https://doi.org/10.1186/s13321-018-0283-x
- El-Kabbani, O., Carbone, V., Darmanin, C., Oka, M., Mitschler, A., Podjarny, A., Schulze-Briese, C., & Chung, R. P. (2005). Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity. Journal of Medicinal Chemistry, 48(17), 5536–5542. https://doi.org/https://doi.org/10.1021/jm050412o
- Füllbeck, M., Michalsky, E., Dunkel, M., & Preissner, R. (2006). Natural products: Sources and databases. Natural Product Reports, 23(3), 347–356. https://doi.org/https://doi.org/10.1039/b513504b
- Gabbay, K. H. (2004). Aldose reductase inhibition in the treatment of diabetic neuropathy: Where are we in 2004? Current Diabetes Reports, 4(6), 405–408. https://doi.org/https://doi.org/10.1007/s11892-004-0047-z
- Gagnon, J. K., Law, S. M., & Brooks, C. L. III. (2016). Flexible CDOCKER: Development and application of a pseudo-explicit structure-based docking method within CHARMM. Journal of Computational Chemistry, 37(8), 753–762. https://doi.org/https://doi.org/10.1002/jcc.24259
- Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449–461. https://doi.org/https://doi.org/10.1517/17460441.2015.1032936
- Ghose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1999). A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of Combinatorial Chemistry, 1(1), 55–68. https://doi.org/https://doi.org/10.1021/cc9800071
- Greenidge, P. A., Kramer, C., Mozziconacci, J. C., & Sherman, W. (2014). Improving docking results via reranking of ensembles of ligand poses in multiple X-ray protein conformations with MM-GBSA. Journal of Chemical Information and Modeling, 54(10), 2697–2717. https://doi.org/https://doi.org/10.1021/ci5003735
- Hoover, W. G. (1985). Canonical dynamics: Equilibrium phase-space distributions. Physical Review A, 31(3), 1695–1697. https://doi.org/https://doi.org/10.1103/physreva.31.1695
- Hotta, N., Sakamoto, N., Shigeta, Y., Kikkawa, R., & Goto, Y. (1996). Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: Multicenter study. Diabetic Neuropathy Study Group in Japan. Journal of Diabetes and Its Complications, 10(3), 168–172. https://doi.org/https://doi.org/10.1016/1056-8727(96)00113-4
- Howard, E. I., Sanishvili, R., Cachau, R. E., Mitschler, A., Chevrier, B., Barth, P., Lamour, V., Van Zandt, M., Sibley, E., Bon, C., Moras, D., Schneider, T. R., Joachimiak, A., & Podjarny, A. (2004). Ultrahigh resolution drug design I: Details of interactions in human aldose reductase-inhibitor complex at 0.66 A. Proteins: Structure, Function, and Bioinformatics, 55(4), 792–804. https://doi.org/https://doi.org/10.1002/prot.20015
- Huang, X., & Powers, R. (2001). Validity of using the radius of gyration as a restraint in NMR protein structure determination. Journal of the American Chemical Society, 123(16), 3834–3835. https://doi.org/https://doi.org/10.1021/ja005770p
- Karplus, M., & McCammon, J. A. (2002). Molecular dynamics simulations of biomolecules. Nature Structural & Molecular Biology, 9(9), 646. https://doi.org/https://doi.org/10.1038/nsb0902-646
- Kumar, M., Choudhary, S., Singh, P. K., & Silakari, O. (2020). Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications. Future Medicinal Chemistry, 12(14), 1327–1358. https://doi.org/https://doi.org/10.4155/fmc-2020-0032
- Kumar, H., Shah, A., & Sobhia, M. E. (2012). Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors. Journal of Molecular Modeling, 18(5), 1791–1799. https://doi.org/https://doi.org/10.1007/s00894-011-1195-0
- Kurogi, Y., & Guner, O. F. (2001). Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Current Medicinal Chemistry, 8(9), 1035–1055. https://doi.org/https://doi.org/10.2174/0929867013372481
- Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1–3), 3–25. https://doi.org/https://doi.org/10.1016/S0169-409X(96)00423-1
- Ma, D.-L., Chan, D. S.-H., & Leung, C.-H. (2011). Molecular docking for virtual screening of natural product databases. Chemical Science, 2(9), 1656–1665. https://doi.org/https://doi.org/10.1039/C1SC00152C
- Manzanaro, S., Salvá, J., & de la Fuente, J. Á. (2006). Phenolic marine natural products as aldose reductase inhibitors. Journal of Natural Products, 69(10), 1485–1487. https://doi.org/https://doi.org/10.1021/np0503698
- Miyamoto, S. (2002). Molecular modeling and structure-based drug discovery studies of aldose reductase inhibitors. Chem-Bio Informatics Journal, 2(3), 74–85. https://doi.org/https://doi.org/10.1273/cbij.2.74
- Morsi, M., Kobeissy, F., Magdeldin, S., Maher, A., Aboelmagd, O., Johar, D., & Bernstein, L. (2019). A shared comparison of diabetes mellitus and neurodegenerative disorders. Journal of Cellular Biochemistry, 120(9), 14318–14325. https://doi.org/https://doi.org/10.1002/jcb.26261
- Nosé, S., & Klein, M. L. (1983). A study of solid and liquid carbon tetrafluoride using the constant pressure molecular dynamics technique. The Journal of Chemical Physics, 78(11), 6928–6939. https://doi.org/https://doi.org/10.1063/1.444641
- Oloff, S., Mailman, R. B., & Tropsha, A. (2005). Application of validated QSAR models of D1 dopaminergic antagonists for database mining. Journal of Medicinal Chemistry, 48(23), 7322–7332. https://doi.org/https://doi.org/10.1021/jm049116m
- Oprea, T. I. (2000). Property distribution of drug-related chemical databases. Journal of Computer-Aided Molecular Design, 14(3), 251–264. https://doi.org/https://doi.org/10.1023/A:1008130001697
- Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, R., Skeel, R. D., Kale, L., & Schulten, K. (2005). Scalable molecular dynamics with NAMD. Journal of Computational Chemistry, 26(16), 1781–1802. https://doi.org/https://doi.org/10.1002/jcc.20289
- Quattrini, L., & La Motta, C. (2019). Aldose reductase inhibitors: 2013-present. Expert Opinion on Therapeutic Patents, 29(3), 199–213. https://doi.org/https://doi.org/10.1080/13543776.2019.1582646
- Ramirez, M. A., & Borja, N. L. (2008). Epalrestat: An aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 28(5), 646–655. https://doi.org/https://doi.org/10.1592/phco.28.5.646
- Rastelli, G., Ferrari, A. M., Costantino, L., & Gamberini, M. C. (2002). Discovery of new inhibitors of aldose reductase from molecular docking and database screening. Bioorganic & Medicinal Chemistry, 10(5), 1437–1450. https://doi.org/https://doi.org/10.1016/S0968-0896(01)00410-2
- Rogers, D., & Hopfinger, A. J. (1994). Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. Journal of Chemical Information and Modeling, 34(4), 854–866. https://doi.org/https://doi.org/10.1021/ci00020a020
- Seferovic, J. P., Bentley-Lewis, R., Claggett, B., Diaz, R., Gerstein, H. C., Køber, L. V., Lawson, F. C., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., Probstfield, J. L., Riddle, M. C., Solomon, S. D., Tardif, J.-C., & Pfeffer, M. A. (2018). Retinopathy, neuropathy, and subsequent cardiovascular events in patients with type 2 diabetes and acute coronary syndrome in the ELIXA: The importance of disease duration. Journal of Diabetes Research, 2018, 1631263. https://doi.org/https://doi.org/10.1155/2018/1631263
- Shemetulskis, N. E., Dunbar, J. B., Dunbar, B. W., Moreland, D. W., & Humblet, C. (1995). Enhancing the diversity of a corporate database using chemical database clustering and analysis. Journal of Computer-Aided Molecular Design, 9(5), 407–416. https://doi.org/https://doi.org/10.1007/BF00123998
- Steele, J. W., Faulds, D., & Goa, K. L. (1993). Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus. Drugs & Aging, 3(6), 532–555. https://doi.org/https://doi.org/10.2165/00002512-199303060-00007
- Steindl, T., & Langer, T. (2004). Influenza virus neuraminidase inhibitors: Generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening. Journal of Chemical Information and Computer Sciences, 44(5), 1849–1856. https://doi.org/https://doi.org/10.1021/ci049844i
- Triballeau, N., Acher, F., Brabet, I., Pin, J. P., & Bertrand, H. O. (2005). Virtual screening workflow development guided by the “receiver operating characteristic” curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. Journal of Medicinal Chemistry, 48(7), 2534–2547. https://doi.org/https://doi.org/10.1021/jm049092j
- UK Prospective Diabetes Study Group. (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ: British Medical Journal, 317(7160), 703–713. https://doi.org/https://doi.org/10.1136/bmj.317.7160.703
- Varma, M. V., Obach, R. S., Rotter, C., Miller, H. R., Chang, G., Steyn, S. J., El-Kattan, A., & Troutman, M. D. (2010). Physicochemical space for optimum oral bioavailability: Contribution of human intestinal absorption and first-pass elimination. Journal of Medicinal Chemistry, 53(3), 1098–1108. https://doi.org/https://doi.org/10.1021/jm901371v
- Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615–2623. https://doi.org/https://doi.org/10.1021/jm020017n
- Volpe, C. M. O., Villar-Delfino, P. H., dos Anjos, P. M. F., & Nogueira-Machado, J. A. (2018). Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death & Disease, 9(2), 119. https://doi.org/https://doi.org/10.1038/s41419-017-0135-z
- Vyas, B., Choudhary, S., Singh, P. K., Singh, A., Singh, M., Verma, H., Singh, H., Bahadur, R., Singh, B., & Silakari, O. (2018). Molecular dynamics/quantum mechanics guided designing of natural products based prodrugs of Epalrestat. Journal of Molecular Structure, 1171, 556–563. https://doi.org/https://doi.org/10.1016/j.molstruc.2018.06.030
- Vyas, V. K., Ghate, M., & Goel, A. (2013). Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors. Journal of Molecular Graphics and Modelling, 42, 17–25. https://doi.org/https://doi.org/10.1016/j.jmgm.2013.01.010
- Wang, Z., Ling, B., Zhang, R., Suo, Y., Liu, Y., Yu, Z., & Liu, C. (2009). Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase. Journal of Molecular Graphics & Modelling, 28(2), 162–169. https://doi.org/https://doi.org/10.1016/j.jmgm.2009.06.003
- Whittle, M., Willett, P., Klaffke, W., & van Noort, P. (2003). Evaluation of similarity measures for searching the dictionary of natural products database. Journal of Chemical Information and Computer Sciences, 43(2), 449–457. https://doi.org/https://doi.org/10.1021/ci025591m
- Wu, G., Robertson, D. H., Brooks, C. L., III, & Vieth, M. (2003). Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. Journal of Computational Chemistry, 24(13), 1549–1562. https://doi.org/https://doi.org/10.1002/jcc.10306
- Yan, L. j. (2018). Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Models and Experimental Medicine, 1(1), 7–13. https://doi.org/https://doi.org/10.1002/ame2.12001
- Zhang, L., Zhang, H., Zhao, Y., Li, Z., Chen, S., Zhai, J., Chen, Y., Xie, W., Wang, Z., Li, Q., Zheng, X., & Hu, X. (2013). Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: Role of Trp112 (Trp111).FEBS Letters, 587(22), 3681–3686. https://doi.org/https://doi.org/10.1016/j.febslet.2013.09.031